Life Sciences Cos. Should Look Past Litigation During COVID
Disputes between business partners have always been particularly disruptive for life sciences companies.
Long-term, complex relationships with multiple research, development and commercialization partners; global supply chains; lengthy times to market involving massive investment and risk; and other features have always made litigation and lengthy, litigation-lite arbitrations problematic.
Full Article Below:
This page is for general information purposes. JAMS makes no representations or warranties regarding its accuracy or completeness. Interested persons should conduct their own research regarding information on this website before deciding to use JAMS, including investigation and research of JAMS neutrals. See More